Hepion Pharmaceuticals, Inc.
For the period ended Mar 31, 2025. Filed May 19, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 19, 2025
HEPA$0.11-13.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Balance Sheets
CONDENSED CONSOLIDATED BALANCE SHEETS
| March 31, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash | $4,586,389 | $406,408 |
| Prepaid expenses | 1,732,166 | 1,207,329 |
| Total current assets | 6,318,555 | 1,613,737 |
| Total assets | $6,318,555 | $1,613,737 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $243,259 | $220,202 |
| Accrued expenses | 166,487 | 23,684 |
| Notes payable, current | 526,178 | 2,900,000 |
| Total current liabilities | 935,924 | 3,143,886 |
| Derivative financial instruments-warrants | 1,486,568 | 333,189 |
| Total liabilities | 2,422,492 | 3,477,075 |
| Commitments and contingencies (see Note 10) | - | |
| Stockholders’ equity: | ||
| Series A convertible preferred stock, stated value $10 per share, 85,581 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively | 855,808 | 855,808 |
| Series C convertible preferred stock, stated value $1,000 per share, 1,688 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively | 839,320 | 839,320 |
| Common stock—$0.0001 par value per share; 120,000,000 shares authorized, 9,588,908 and 139,168 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively. | 959 | 14 |
| Additional paid-in capital | 246,117,324 | 234,252,981 |
| Accumulated other comprehensive income | 8,345 | 8,345 |
| Accumulated deficit | (243,925,693) | (237,819,806) |
| Total stockholders’ equity | 3,896,063 | (1,863,338) |
| Total liabilities and stockholders’ equity | $6,318,555 | $1,613,737 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.